GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

ASP Isotopes ASPI · USD

Materials · US listing · 🇺🇸 United States

Compare

2.14

+2.88%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About ASP Isotopes

From its filings with the US Securities and Exchange Commission

SEC filings

ASP Isotopes is based in Dallas, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ASPI. The SEC classifies its business as miscellaneous chemical products. In the fiscal year to 31 December 2025, it reported revenue of $23.8m and a net loss of $159.8m. At that date it held total assets of $498.0m and shareholders' equity of $204.2m.

In its own words

We are an advanced materials company dedicated to the development of a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy. In addition, in January 2026, we acquired Renergen, which is South Africa’s leading onshore natural gas explorer and the first integrated producer of both liquid helium and LNG (as discussed further below). Our proprietary enrichment technologies, the Aerodynamic Separation Process (“ASP technology”) and Quantum Enrichment technology (“QE technology”), are designed to enable the production of isotopes for a range of industrial and advanced technology applications. Our initial focus with respect to our isotope enrichment platform is on the production and commercialization of enriched Carbon-14 (“C-14”), Silicon-28 (“Si-28”) and Ytterbium-176 (“Yb-176”).

We commenced commercial production of enriched isotopes at both of our ASP enrichment facilities located in Pretoria, South Africa during the first half of 2025. Our first ASP enrichment facility is designed to enrich light isotopes, such as C-14 and C-12. The second ASP enrichment facility, which is substantially larger than the first, should have the potential to enrich kilogram quantities of relatively heavier isotopes, including but not limited to Si-28. We are targeting initial commercial shipments of enriched C-14 in mid-2026. We are targeting initial commercial shipments of enriched Si-28 during the second quarter of 2026.

Quoted from its 10-K, filed 10 Apr 2026. Read the filing on SEC.gov ↗

Company facts

Sector
Materials
Industry
Chemicals
Listed since
10 Nov 2022
Employees
271
Head office
2200 ROSS AVENUE, SUITE 4575E, DALLAS, TX, 75201
Incorporated in
DE
Classification
Miscellaneous Chemical Products
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Paul MannExecutive Chairman of the Board, since 2021$4.8m
  • Mr. Robert AinscowInterim Chief Executive Officer (Principal Executive Officer), Co-Founder, Chief Operating Officer$1.1m
  • Ms. Heather KiesslingChief Financial Officer$1.7m
  • Dr. Hendrik StrydomChief Technology Officer, since 2022$122,400
  • Prof. Michael GorleyIndependent Director$374,032
  • Mr. Ralph HunterIndependent Director
  • Mr. Sipho MasekoIndependent Director
  • Dr. Duncan MooreIndependent Director$374,032
  • Mr. Robert RyanIndependent Director$374,032
  • Dr. Todd WiderIndependent Director$374,032
  • Mr. Jason AssadInvestor Relations, since 2024

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
13
Environment
8
Social
12
Governance
18
Carbon reduction policy
No
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • ASP Isotopes Inc. has a license for Aerodynamic Separation Process technology from Klydon Proprietary Ltd.
  • The company focuses on enriched Carbon-14, Molybdenum-100, and Silicon-28 products.
  • ASP Isotopes Guernsey Limited develops high value low volume isotopes for specialized markets.

Weaknesses

  • The company is in pre-commercial stage with only 46 full-time employees.
  • ASP Isotopes Inc. has an IPO listing date of 10 November 2022.
  • Enriched Energy LLC is focused on uranium for nuclear energy market development.

Opportunities

  • The company aims to develop enriched Uranium-235 using ASP technology.
  • ASP Isotopes UK Ltd operates in the UK market for isotope commercialization.
  • The firm has a license to use technology for all isotope production and distribution.

Threats

  • The company's initial focus on Carbon-14, Molybdenum-100, and Silicon-28 may face market competition.
  • ASP Isotopes Guernsey Limited operates in a niche specialized market segment.
  • Enriched Energy LLC's uranium development faces regulatory challenges in nuclear energy.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.